Evogene Ltd. (NASDAQ:EVGN)
| Market Cap | 6.49M-69.2% |
| Revenue (ttm) | 1.66M |
| Net Income | -17.83M |
| EPS | -1.60 |
| Shares Out | 15.80M |
| PE Ratio | n/a |
| Forward PE | -0.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,215 |
| Open | 0.43 |
| Previous Close | 0.42 |
| Day's Range | 0.39 - 0.43 |
| 52-Week Range | 0.35 - 1.49 |
| Beta | 0.72 |
| Analysts | Strong Buy |
| Price Target | 2.15(+423.62%) |
| Earnings Date | Nov 19, 2026 |
Evogene Ltd. has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
About EVGN
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$EVGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in EVGN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EVGN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EVGN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New EVGN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EVGN from public contracts
Source: USAspending.gov
EVGN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from EVGN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score